98results about "Apoptosis detection" patented technology

To provide a method allowing g protein-coupled receptors to express and function.SOLUTION: Provided is a method for expressing a GPCR polypeptide. The method comprises expressing in a cell a GPCR polypeptide consisting of an amino acid sequence in which at least one amino acid residue that differs from a consensus amino acid sequence in the amino acid sequence of the target GPCR (excluding olfactory receptors) is modified to an amino acid residue in the consensus amino acid sequence at the corresponding position. Here, the consensus amino acid sequence is an amino acid sequence derived from an alignment of the amino acid sequence of the GPCR of interest and the amino acid sequence of GPCR encoded by an orthologue of the GPCR of interest in a vertebrate.SELECTED DRAWING: None

Nucleotide compositions, recombinant vectors, and recombinant viral genomes are disclosed that include a modified horseradish peroxidase (HRP) gene sequence, as well as recombinant viruses that have the modified HRP gene sequence incorporated into the viral genome thereof. The recombinant viruses are utilized in an HRP-based assay to analyze the neutralization potential of candidate antiviral agents, such as antiviral antibodies.

This disclosure provides methods and reagents useful for analyzing protein-protein interfaces, such as the interface between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophyllin family, or PIN1) and a target protein. [Solution] In some embodiments, the target and / or presenter protein is an intracellular protein. In some embodiments, the target and / or presenter protein is a mammalian protein.

Provided herein are methods amenable to high-throughput multiplexing, in part, using a modified enzyme complementation assay, that can be used to screen a library of test compounds and to identify compounds that inhibit denaturation of a target polypeptide of interest.

To date, there is still a need in this field for more efficient cancer treatment. More specifically, there is still a lack of tools that can be used for more effective cancer immunotherapy. [Solution] The present invention relates to the use of human growth differentiation factor 15 (GDF-15) inhibitors in the treatment of solid tumors, and to the use of such inhibitors in combination with immune checkpoint blockers.

The application provides a pulmonary artery tissue-derived cell, an organoid and a construction method and application thereof. The pulmonary artery intimal stripping tissue organoid structure obtained by the preparation method is clear, has consistent cell types as the source tissue, is close to the original tissue, is convenient for researchers to operate, and thus has good practical application value.

The invention relates to a method to independently identify by fluorescence microscopy different cell types forming multicellular structures in co-culture thanks to a fluorescently-labelled extracellular matrix, and the individual identification of each multicellular structure of the co-culture with a spatial positioning of those structures in microcavities, so as to individually and independently measure multiple biological activities in each multicellular structure of each type of tissue of the co-culture.

The present invention provides a pharmaceutical composition useful for treating a disease caused by a target tissue, its active ingredient, a screening method for the pharmaceutical composition and the active ingredient, and a manufacturing method. [Solution] The present invention provides an antigen-binding molecule comprising an antigen-binding domain whose antigen-binding activity changes depending on the concentration of a target tissue-specific compound. The antigen-binding molecule comprises an Fc region contained in a constant region of a specific sequence, and an FcγR-binding altered Fc region whose binding activity to Fcγ receptors is higher than the binding activity to Fcγ receptors of the Fc region of native human IgG. Use of the antigen-binding molecule enables target tissue-specific treatment of various diseases caused by target tissues.

The present invention relates to a method, in particular an in vitro method, for a method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant, comprising detecting, and quantifying at least one protein in a sulcus fluid sample obtained from said subject that is enriched or depleted in the sample when compared to a sulcus fluid sample obtained from a healthy implant (I) and / or a healthy tooth (T), wherein an enrichment of at least one protein as identified and / or wherein a depletion of at least one protein as identified detects a PI in said subject. Furthermore, the present invention relates to the application of the findings of the invention in the development of new anti-PI therapies and as well as to a kit for performing the above methods as well as respective uses thereof. Finally, improved anti-PI compounds or pharmaceutical compositions are provided.

The present invention provides a composition for diagnosing age-related macular degeneration (AMD) using proteomic analysis and biomarkers, a method for providing information for diagnosing AMD, and a method for screening substances for treating AMD, wherein the composition for diagnosing age-related macular degeneration (AMD), includes a preparation for measuring the mRNA or protein expression level of an age-related macular degeneration-related biomarker.

The present invention relates to agents for measuring the expression of proteins or genes encoding the proteins that are exclusively or specifically expressed in circulating tumor cells, or methods for preventing or treating cancer metastasis by controlling the expression of the proteins or the genes. The present invention provides a method for detecting cancer or cancer metastasis by identifying proteins or genes encoding proteins that are exclusively or specifically expressed in circulating tumor cells, and measuring their expression, and ultimately, may be effectively used for efficient prevention or treatment of cancer metastasis by inhibiting their expression.

To provide a biological culture chip suitable even for complex detection of cell biological functions such as antibody secretion and growth factor secretion.SOLUTION: Provided is a biological culture chip including a matrix formed of a matrix material, and culture chambers formed on a surface of the matrix to define the culture chambers, the matrix material of the matrix having an equilibrium swelling ratio of 1.25 to 1.75 and the culture chambers being formed in openings configured on the surface of the matrix to define the culture chambers.SELECTED DRAWING: Figure 3

It was found that enhancement of Plk1 activity induces lethal abnormalities in chromosome dynamics in cancer cells, causing the growth to be suppressed. Therefore, activating Plk1 and exacerbating chromosome instability can lead to lethal abnormalities in chromosome dynamics and suppress the growth of cancer cells. Provided are a method for screening a medicine and a pharmaceutical composition based on a new drug discovery concept in which activating a kinase that exhibits enhanced expression in cancer cells causes the suppression of cancer cell growth.

The present invention relates to methods and compositions for treating and / or preventing a disease or disorder associated with abnormally high level of the IFP35 family of proteins, including IFP35 and NMI, methods and compositions for diagnosis, prognosis or treatment monitoring of a disease or disorder associated with abnormally high level of the IFP35 family of proteins, including IFP35 and NMI, and methods and compositions for identifying a modulator of the IFP35 family of proteins, including IFP35 and NMI.

A use of a Cf48 small peptide, as a marker for kidney injury condition, in a diagnosis kit; a use of the Cf48 small peptide as a drug intervention target in the preparation of a drug for treating kidney injury; and a system for evaluating the kidney injury condition on the basis of Cf48. The sequence encoding the Cf48 small peptide is SEQ ID NO: 1. The Cf48 small peptide can be used as a marker for one or more of kidney disease diagnosis, kidney injury degree determination, prognosis prediction, renal fibrosis degree determination, and renal fibrosis activity determination. For a novel kidney disease injury diagnosis marker and a diagnosis kit, the kidney injury condition can be determined by detecting the content of Cf48 in kidney tissues and blood. The Cf48 small peptide has high specificity, the defect in the prior art that the kidney injury condition is basically determined by biopsy and pathology is overcome, the detection is convenient, and the result is accurate.

The application discloses a method for differentiating stem cells into caudal serotonergic neurons, a complete culture medium and application. Specifically, a new culture medium is formed by adding small molecule compounds, so that human pluripotent stem cells are gradually induced to obtain hindbrain neural stem cells, ventral hindbrain caudal neural stem cells, serotonergic precursor cells and caudal serotonergic neurons of the hindbrain. The culture method is simple, and can efficiently obtain mature serotonergic neurons of specific regions, thereby providing an effective cell model for research on diseases related to the serotonergic system.

The application provides application of a modified form of WDHD1, WDHD1 S141 phosphorylation, as a biomarker in preparation of a liver cancer early diagnosis or prognosis reagent. The application also provides a kit for quantitatively or semi-quantitatively detecting a protein, which contains an antibody capable of specifically amplifying the WDHD1 S141 phosphorylation. The application can more effectively preliminarily evaluate and predict the condition of a subject suffering from liver cancer by detecting the expression level of the WDHD1 S141 phosphorylation. The application will help improve the diagnosis accuracy of liver cancer and provide an important basis for early treatment of patients. The kit can be applied to the diagnosis of early, middle and late liver cancer. The application also provides application of the WDHD1 S141 phosphorylation in preparation of a liver cancer treatment drug.

The invention relates to a synthetic platform for mimicking at least one type of interaction between a cuticular protein and a cuticulotropic agent occurring in the natural buccal cuticle of a terrestrial arthropod. The platform comprises a chitosan film in which at least one cuticular protein present in the natural cuticle of said terrestrial arthropod is encapsulated, while remaining accessible for interaction with at least said cuticulotropic agent. The invention also relates to methods for its fabrication and in vitro evaluation and identification methods using the platform. Figure for abstract: none

Disclosed herein are methods and compositions useful in screening a compound for its effect on proteotoxicity and proteinaceous inclusions involved in neurological disease.

A method of generating a plurality of different surface-decorated nanoparticles, decorated with different surface decoration, comprising: forming a plurality of microdroplets in a microfluidics device, each microdroplet comprising a nanoparticle and a respectively different macromolecule encoding a different surface decoration molecule; synthesising the surface decoration molecule, within each microdroplet, based on the macromolecule encoding the surface decoration molecule; conjugating the nanoparticle and the surface decoration molecule, within each microdroplet, to form surface decorated nanoparticles.

A compound of formula I:wherein A is present or absent; X1, X2, X3 and X4 are, independently from each other, an alkyl;Y1, Y2, Y3 and Y4 are independently from each other a C1-C10 alkyl, —Z1, Z2, Z3 and Z4 are independently from each other a C1-C5 linear alkyl; R1 is a group allowing to carry out bioorthogonal reactions; and R2 is group including a N.

An imaging flow cytometry-based high-throughput drug screening method, comprising: cell incubation, cell staining, acquiring single-cell images by means of a flow cytometer, and image extraction and analysis, which combines the high-throughput advantages of flow cytometry and the imaging capability of a microscope, so that multi-channel single-cell images can be generated in a high throughput manner, thereby implementing acquisition of fluorescent images and unmarked images of single cells at a throughput of 102-105 cells per second, which can be used for cell phenotype drug screening and improving the screening efficiency by a factor of 102-104.

The application provides application of a reagent for detecting a marker in preparation of a product for diagnosing and / or predicting chronic obstructive pulmonary disease. The marker of the application is any one or more of NOSIP, AGMAT and LINC01215. It is found for the first time that NOSIP, AGMAT and / or LINC01215 are significantly differentially expressed between blood samples of patients with chronic obstructive pulmonary disease and normal persons. Whether NOSIP, AGMAT and / or LINC01215 are differentially expressed in blood of a subject can be detected as a method for early diagnosis of chronic obstructive pulmonary disease. Accordingly, tools and products for early diagnosis of chronic obstructive pulmonary disease can be developed, which are of great significance for guiding prevention and screening of high-risk groups of chronic obstructive pulmonary disease.

The present invention relates to an agent for inhibiting the expression or activity of G protein-coupled receptor 182 (GPR182) protein for use in the treatment or prevention of a pathological condition selected from myocardial infarction, myocardial ischemia, myocardial necrosis, cardiac hypertrophy, cardiac fibrosis, limb ischemia, ischemia-related tissue degeneration, stroke, and cancer, wherein (a) the agent for inhibiting the expression of GPR182 protein is selected from siRNA, miRNA, shRNA, ribozyme, and antisense nucleic acid molecules; and / or (b) the agent for inhibiting the activity of GPR182 protein specifically binds to the GPR182 protein and inhibits the binding of one or more endogenous ligands to the GPR182 protein, and the agent is selected from an antibody, Fc fusion polypeptide, adnectin, affibody, affilin, anticalin, atrimer, avimer, evibody, Kunitz-type domain, designed ankyrin repeat protein (DARPin), finomer, peptide or peptidomimetic, aptamer, and small molecule; or any combination thereof and / or a hetero- or homo-oligomeric covalent or non-covalent complex.

The present application relates to methods for quantifying citrullination and methods that can be used to assess the activity of agents, including, for example, PAD4 (peptidyl arginine deiminase 4) modulators, such as small molecules or antibodies. In certain embodiments, the methods include assessing citrullination at one or more citrullination sites on a protein or peptide fragment thereof present in a biological sample.

Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furthermore, the present invention also relates to a method for preventing and / or treating RSV infections or diseases and / or symptoms caused by RSV infections by means of using the fusion protein, nucleic acid molecule and vaccine.

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

This disclosure relates to a method for determining the potency of an effector cell composition, such as a therapeutic cell composition, for use in conjunction with cell therapy, based on cytotoxicity. The cells of the cell composition may express recombinant receptors, such as chimeric receptors, such as chimeric antigen receptors (CARs), or other transgenic receptors such as T cell receptors (TCRs). The method provides a cytotoxicity assay for identifying the potency of the cell composition, including relative potency.

A method of evaluating an effect of at least one agent on an organoid is disclosed herein. The method includes providing the organoid in a cell culture or microfluidic platform, contacting the organoid with at least one agent, acquiring a plurality of images of the organoid and a control organoid, and analyzing the plurality of images for a change of at least one characteristic of the organoid, wherein the change of the at least one characteristic is indicative of a disease or a disorder, and wherein the analyzing comprises comparing the organoid to the control organoid to determine the change of the at least one characteristic. The method also includes assessing the effect of the at least one agent at least in part on the change of the at least one characteristic of the organoid.

The present invention is directed to a biological marker of ovarian cancer, including early stage ovarian cancer. Specifically, the present invention provides methods for detecting ovarian cancer in a subject which include detecting an expression level of the biological marker junction plakoglobin in blood of the subject. An expression level of junction plakoglobin that is higher than a reference expression level for junction plakoglobin indicates that the subject has ovarian cancer. Methods of identifying a subject having ovarian cancer and methods of determining if a subject is susceptible to developing ovarian cancer are also provided based on detecting the expression level of junction plakoglobin in blood of the subject. The present invention also extends to methods of treatment of ovarian cancer together with methods of screening a candidate therapeutic agent for use in treating ovarian cancer. Furthermore, compositions and kits for detecting ovarian cancer in a subject are provided, as well as a method of identifying a biomarker for a cancer, including ovarian cancer.